OXIS International, Inc. Announces its Attendance at the Rodman & Renshaw Annual Global Investment Conference in New York, September 12-15, 2010
BEVERLY HILLS, Calif., Aug. 18 /PRNewswire-FirstCall/ — OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI), announced today that its senior management will be presenting at the Rodman & Renshaw Annual Global Investment Conference September 12th-15th. Chairman & CEO Tony Cataldo will introduce Oxis’ new product line which leverages its patented super antioxidant Ergothioneine. Oxis continues to gain momentum in the multibillion dollar Nutraceuticals, Functional Food, Cosmeceuticals, and Animal Health markets and is expected to attract substantial attention from the over 1,000 institutional investors attending the conference.
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.
This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company’s filings with the Securities and Exchange Commission.
SOURCE OXIS International, Inc.